AbbVie (ABBV) has just reported a cluster of regulatory milestones, including positive European opinions for Rinvoq in severe alopecia areata and non segmental vitiligo, as well as new pediatric approvals for Skyrizi in psoriasis and psoriatic arthritis.

These regulatory wins have arrived during a strong period for AbbVie, with the latest share price at US$254.31 and a 30 day share price return of 16.81% feeding into a 1 year total shareholder return of 41.47%. This suggests momentum has been building around the stock alongside recent index additions and product updates.

If AbbVie’s recent run in immunology and dermatology has your attention, this is a good moment to see what else is moving in healthcare and immunology focused AI, starting with the 41 healthcare AI stocks

With AbbVie trading at US$254.31 after a 41.47% 1-year total shareholder return and sitting almost exactly in line with the average analyst price target, the key question now is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 0% Overvalued

AbbVie is trading at $254.31, almost exactly in line with a narrative fair value estimate of $253.55, which anchors analyst expectations for the stock.

AbbVie''s diversified and expanding late-stage and early-stage pipeline, coupled with consistent business development activity (e.g., Capstan in vivo CAR-T, Gubra amylin analog for obesity, next-gen siRNA platforms), positions the company to capitalize on the increasing adoption of biologics and specialty pharmaceuticals, which can reinforce premium pricing and protect net margins.

Want to see how this pipeline story turns into a specific fair value for AbbVie? Revenue trajectories, margin rebuild and future earnings multiples all sit at the core of this narrative. The assumptions behind those three levers may surprise you.

Result: Fair Value of $253.55 (ABOUT RIGHT)

However, there are still key AbbVie risks to watch, particularly pressure on drug pricing and the possibility that big ticket deals like Apogee underdeliver on expectations.

Another View: AbbVie Through the SWS DCF Model

The narrative fair value for AbbVie of about $253.55 suggests the current $254.31 share price is roughly in line with expectations. However, the SWS DCF model points to a fair value of $434.69, which frames AbbVie as trading at a sizeable discount. Which story do you trust more: the narrative consensus, or the cash flow math?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AbbVie for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 42 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Reading this AbbVie story, are you leaning more cautious or optimistic? If you want to move quickly and test your own view against the underlying data, start by weighing the company’s 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond AbbVie?

If AbbVie has sharpened your focus, do not stop here. Use these hand picked stock ideas to broaden your watchlist and pressure test your next move.

• Target resilient compounding potential with the 70 resilient stocks with low risk scores to see stocks that score well on stability and downside protection.
• Hunt for quality at a sensible price using the 42 high quality undervalued stocks to spot companies that align strong fundamentals with appealing valuations.
• Strengthen your income toolkit by reviewing the 9 dividend fortresses to find higher yielding stocks that may suit a cash flow focused portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.